Cancer Registry Software Market by Type (Standalone, Integration), Delivery (On-premise, Cloud), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care, Medical Research), End User, Region - Global Forecast to 2024
“Cancer patient registry software market projected to grow at a CAGR of 10.4%”
The cancer patient registry software market is projected to reach USD 91 million by 2024 from USD 55 million in 2019, at a CAGR of 10.4%. Factors such as the growing prevalence of cancer, favorable government initiatives, rising adoption of EHRs, growing use of cancer patient registry data for post-marketing surveillance, and rising pressure to improve the quality of care and reduce healthcare costs are driving the growth of this market. However, privacy and data security-related concerns may restrain the growth of this market to a certain extent.
“The on-premise model segment accounted for the largest share of the cancer patient registry software market, by deployment model, in 2018”
Based on deployment model, the cancer patient registry software market is segmented into on-premise and cloud-based models. The on-premise model segment dominated this market in 2018 primarily due to the higher adoption of on-premise solutions among end users as a result of advantages such as high security, low risk of external attacks and data breaches, and control over software upgrades. Also, this model enables flexibility of the connection bandwidth—a very important feature in cases where a client is dealing with heavy data file transfers.
“Commercial databases accounted for the largest share of the cancer patient registry software market, by database type, in 2018”
Based on the type of database, the cancer patient registry software market is segmented into commercial and public databases. The commercial databases segment dominated this market in 2018 owing to the ease of expansion of these databases, which allows a large user base to access, add, or modify information simultaneously. Also, owing to the advantages offered by commercial databases, a large number of pharmaceutical and medical device companies are opting for these databases.
“The medical research & clinical studies segment to witness the highest growth in the cancer patient registry software market, by functionality, during the forecast period”
Based on functionality, the cancer patient registry software market is segmented into cancer reporting to meet state and federal regulations, patient care management, product outcome evaluation, and medical research & clinical studies. The ability of cancer registries to provide data complementary to that obtained from trials for supporting medical research and clinical studies is one of the major factors driving the demand for cancer patient registry software for medical research and clinical studies.
“North American market to witness high growth during the forecast period”
In 2018, North America was the largest regional market for cancer patient registry software. This market is also estimated to grow at a higher CAGR during the forecast period. The high growth of this regional market can be attributed to the high burden of cancer, government funding initiatives to encourage the development of cancer registries, high investments in healthcare IT, presence of major cancer registry software-developing players, and the high adoption rate of these solutions in the region.
The primary interviews conducted for this report can be categorized as follows:
This report aims at estimating the size and future growth potential of the market across different segments, such as type, deployment model, database, functionality, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report
This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cancer patient registry software market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.
The cancer patient registry software market is projected to reach USD 91 million by 2024 from USD 55 million in 2019, at a CAGR of 10.4%. Factors such as the growing prevalence of cancer, favorable government initiatives, rising adoption of EHRs, growing use of cancer patient registry data for post-marketing surveillance, and rising pressure to improve the quality of care and reduce healthcare costs are driving the growth of this market. However, privacy and data security-related concerns may restrain the growth of this market to a certain extent.
“The on-premise model segment accounted for the largest share of the cancer patient registry software market, by deployment model, in 2018”
Based on deployment model, the cancer patient registry software market is segmented into on-premise and cloud-based models. The on-premise model segment dominated this market in 2018 primarily due to the higher adoption of on-premise solutions among end users as a result of advantages such as high security, low risk of external attacks and data breaches, and control over software upgrades. Also, this model enables flexibility of the connection bandwidth—a very important feature in cases where a client is dealing with heavy data file transfers.
“Commercial databases accounted for the largest share of the cancer patient registry software market, by database type, in 2018”
Based on the type of database, the cancer patient registry software market is segmented into commercial and public databases. The commercial databases segment dominated this market in 2018 owing to the ease of expansion of these databases, which allows a large user base to access, add, or modify information simultaneously. Also, owing to the advantages offered by commercial databases, a large number of pharmaceutical and medical device companies are opting for these databases.
“The medical research & clinical studies segment to witness the highest growth in the cancer patient registry software market, by functionality, during the forecast period”
Based on functionality, the cancer patient registry software market is segmented into cancer reporting to meet state and federal regulations, patient care management, product outcome evaluation, and medical research & clinical studies. The ability of cancer registries to provide data complementary to that obtained from trials for supporting medical research and clinical studies is one of the major factors driving the demand for cancer patient registry software for medical research and clinical studies.
“North American market to witness high growth during the forecast period”
In 2018, North America was the largest regional market for cancer patient registry software. This market is also estimated to grow at a higher CAGR during the forecast period. The high growth of this regional market can be attributed to the high burden of cancer, government funding initiatives to encourage the development of cancer registries, high investments in healthcare IT, presence of major cancer registry software-developing players, and the high adoption rate of these solutions in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 28%; Tier 2 - 19%; and Tier 3 - 53%
- By Designation: C-level - 51%; D-level - 28%; and Others - 21%
- By Region: North America - 70%; Europe - 30%
- Elekta (Sweden)
- Electronic Registry Systems, Inc. (US)
- Onco, Inc. (US)
- C/NET Solutions (US)
- Rocky Mountain Cancer Data Systems (US)
- McKesson Corporation (US)
This report aims at estimating the size and future growth potential of the market across different segments, such as type, deployment model, database, functionality, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report
This report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cancer patient registry software market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY SOURCES
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 CANCER PATIENT REGISTRY SOFTWARE: MARKET OVERVIEW
4.2 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE
4.3 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL
4.4 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE
4.5 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY
4.6 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 Growing prevalence of cancer and favorable government initiatives
5.2.1.2 Rising pressure to improve the quality of care and reduce healthcare costs
5.2.1.3 Rising adoption of EHRs
5.2.1.4 Growing use of cancer patient registry data for post-marketing surveillance
5.2.2 MARKET RESTRAINTS
5.2.2.1 Privacy and data security-related concerns
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Rising number of accountable care organizations
5.2.3.2 Growth of cloud-based cancer patient registry solutions
5.2.4 MARKET CHALLENGES
5.2.4.1 Lack of interoperability and integration
5.2.4.2 Reluctance to adopt advanced solutions
5.2.4.3 Lack of awareness
6 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE
6.1 INTRODUCTION
6.2 STANDALONE SOFTWARE
6.2.1 STANDALONE SOFTWARE ACCOUNTS FOR THE LARGEST SHARE OF THE MARKET
6.3 INTEGRATED SOFTWARE
6.3.1 ADVANTAGES SUCH AS FLEXIBILITY AND SAFETY ARE DRIVING THE ADOPTION OF INTEGRATED SOFTWARE
7 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL
7.1 INTRODUCTION
7.2 ON-PREMISE MODELS
7.2.1 ON-PREMISE MODELS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018
7.3 CLOUD-BASED MODELS
7.3.1 COST-EFFECTIVENESS AND FLEXIBILITY HAVE ENSURED THE GROWTH OF CLOUD-BASED MODELS
8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE
8.1 INTRODUCTION
8.2 COMMERCIAL DATABASES
8.2.1 COMMERCIAL DATABASES SEGMENT HOLD THE LARGEST SHARE IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET
8.3 PUBLIC DATABASES
8.3.1 PUBLIC DATABASES ARE USED FOR DATA COLLECTION FOR A SPECIFIC RESEARCH AGENDA
9 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY
9.1 INTRODUCTION
9.2 CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS
9.2.1 STRINGENT AND RAPIDLY CHANGING STATE AND FEDERAL REGULATIONS FOR CANCER REPORTING TO DRIVE THE GROWTH OF THIS SEGMENT
9.3 PATIENT CARE MANAGEMENT
9.3.1 MARKET PLAYERS ARE EXPECTED TO FOCUS ON DEVELOPING SOLUTIONS DESIGNED WITH AUTOMATED PATIENT OUTREACH FACILITY FOR OPTIMUM PATIENT CARE MANAGEMENT
9.4 MEDICAL RESEARCH & CLINICAL STUDIES
9.4.1 SEVERAL RESEARCH ORGANIZATIONS ARE EXPECTED TO SUPPORT AND ENCOURAGE THE CREATION OF REGISTRIES FOR CLINICAL RESEARCH
9.5 PRODUCT OUTCOME EVALUATION
9.5.1 PRODUCT OUTCOME EVALUATION FUNCTIONALITY HAS MAJOR APPLICATIONS IN POST-MARKETING SURVEILLANCE IN THE PHARMACEUTICAL INDUSTRY
10 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER
10.1 INTRODUCTION
10.2 GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS
10.2.1 GROWING GOVERNMENT INITIATIVES TO DRIVE THE DEMAND FOR CANCER PATIENT REGISTRY SOFTWARE IN THIS END-USER SEGMENT
10.3 HOSPITALS & MEDICAL PRACTICES
10.3.1 IMPROVED PATIENT CARE MANAGEMENT OFFERED BY CANCER PATIENT REGISTRY SOFTWARE TO DRIVE ITS DEMAND IN HOSPITALS AND MEDICAL PRACTICES
10.4 PRIVATE PAYERS
10.4.1 ROLE OF CANCER PATIENT REGISTRY SOFTWARE IN THE EFFECTIVE DETERMINATION OF HEALTHCARE COVERAGE POLICIES TO DRIVE ITS DEMAND AMONG PAYERS
10.5 PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES
10.5.1 INCREASED NEED FOR POST-MARKETING SURVEILLANCE DRIVING THE DEMAND FOR CANCER PATIENT REGISTRY SOFTWARE IN THIS END-USER SEGMENT
10.6 RESEARCH CENTERS
10.6.1 CANCER PATIENT REGISTRY SOFTWARE MAKES IT EASIER FOR RESEARCH CENTERS TO GATHER RELEVANT INFORMATION ON CANCER PATIENTS
11 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Rising adoption of EHRs and increased government funding to build cancer registries—key drivers for market growth
11.2.2 CANADA
11.2.2.1 Government initiatives to encourage cancer research and support data collection for cancer registries to contribute to market growth
11.3 EUROPE
11.3.1 UK
11.3.1.1 Initiatives to promote and develop cancer registration in the UK to drive the growth of this market
11.3.2 GERMANY
11.3.2.1 Growing incidence of cancer and ongoing research activities to drive demand for registry software
11.3.3 FRANCE
11.3.3.1 Growing emphasis on healthcare interoperability to drive the market for integrated cancer patient registry software in France
11.3.4 REST OF EUROPE (ROE)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET PLAYER RANKING
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 PRODUCT ENHANCEMENTS
12.3.2 ACQUISITIONS
12.3.3 COLLABORATIONS
13 COMPANY PROFILES
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 ONCO, INC.
13.2 C/NET SOLUTIONS
13.3 ELEKTA AB (PUB)
13.4 ROCKY MOUNTAIN CANCER DATA SYSTEMS
13.5 ELECTRONIC REGISTRY SYSTEMS, INC.
13.6 MCKESSON CORPORATION
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 RELATED REPORTS
14.4 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY SOURCES
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 CANCER PATIENT REGISTRY SOFTWARE: MARKET OVERVIEW
4.2 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE
4.3 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL
4.4 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE
4.5 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY
4.6 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 Growing prevalence of cancer and favorable government initiatives
5.2.1.2 Rising pressure to improve the quality of care and reduce healthcare costs
5.2.1.3 Rising adoption of EHRs
5.2.1.4 Growing use of cancer patient registry data for post-marketing surveillance
5.2.2 MARKET RESTRAINTS
5.2.2.1 Privacy and data security-related concerns
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Rising number of accountable care organizations
5.2.3.2 Growth of cloud-based cancer patient registry solutions
5.2.4 MARKET CHALLENGES
5.2.4.1 Lack of interoperability and integration
5.2.4.2 Reluctance to adopt advanced solutions
5.2.4.3 Lack of awareness
6 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE
6.1 INTRODUCTION
6.2 STANDALONE SOFTWARE
6.2.1 STANDALONE SOFTWARE ACCOUNTS FOR THE LARGEST SHARE OF THE MARKET
6.3 INTEGRATED SOFTWARE
6.3.1 ADVANTAGES SUCH AS FLEXIBILITY AND SAFETY ARE DRIVING THE ADOPTION OF INTEGRATED SOFTWARE
7 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL
7.1 INTRODUCTION
7.2 ON-PREMISE MODELS
7.2.1 ON-PREMISE MODELS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018
7.3 CLOUD-BASED MODELS
7.3.1 COST-EFFECTIVENESS AND FLEXIBILITY HAVE ENSURED THE GROWTH OF CLOUD-BASED MODELS
8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE
8.1 INTRODUCTION
8.2 COMMERCIAL DATABASES
8.2.1 COMMERCIAL DATABASES SEGMENT HOLD THE LARGEST SHARE IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET
8.3 PUBLIC DATABASES
8.3.1 PUBLIC DATABASES ARE USED FOR DATA COLLECTION FOR A SPECIFIC RESEARCH AGENDA
9 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY
9.1 INTRODUCTION
9.2 CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS
9.2.1 STRINGENT AND RAPIDLY CHANGING STATE AND FEDERAL REGULATIONS FOR CANCER REPORTING TO DRIVE THE GROWTH OF THIS SEGMENT
9.3 PATIENT CARE MANAGEMENT
9.3.1 MARKET PLAYERS ARE EXPECTED TO FOCUS ON DEVELOPING SOLUTIONS DESIGNED WITH AUTOMATED PATIENT OUTREACH FACILITY FOR OPTIMUM PATIENT CARE MANAGEMENT
9.4 MEDICAL RESEARCH & CLINICAL STUDIES
9.4.1 SEVERAL RESEARCH ORGANIZATIONS ARE EXPECTED TO SUPPORT AND ENCOURAGE THE CREATION OF REGISTRIES FOR CLINICAL RESEARCH
9.5 PRODUCT OUTCOME EVALUATION
9.5.1 PRODUCT OUTCOME EVALUATION FUNCTIONALITY HAS MAJOR APPLICATIONS IN POST-MARKETING SURVEILLANCE IN THE PHARMACEUTICAL INDUSTRY
10 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER
10.1 INTRODUCTION
10.2 GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS
10.2.1 GROWING GOVERNMENT INITIATIVES TO DRIVE THE DEMAND FOR CANCER PATIENT REGISTRY SOFTWARE IN THIS END-USER SEGMENT
10.3 HOSPITALS & MEDICAL PRACTICES
10.3.1 IMPROVED PATIENT CARE MANAGEMENT OFFERED BY CANCER PATIENT REGISTRY SOFTWARE TO DRIVE ITS DEMAND IN HOSPITALS AND MEDICAL PRACTICES
10.4 PRIVATE PAYERS
10.4.1 ROLE OF CANCER PATIENT REGISTRY SOFTWARE IN THE EFFECTIVE DETERMINATION OF HEALTHCARE COVERAGE POLICIES TO DRIVE ITS DEMAND AMONG PAYERS
10.5 PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES
10.5.1 INCREASED NEED FOR POST-MARKETING SURVEILLANCE DRIVING THE DEMAND FOR CANCER PATIENT REGISTRY SOFTWARE IN THIS END-USER SEGMENT
10.6 RESEARCH CENTERS
10.6.1 CANCER PATIENT REGISTRY SOFTWARE MAKES IT EASIER FOR RESEARCH CENTERS TO GATHER RELEVANT INFORMATION ON CANCER PATIENTS
11 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.1.1 Rising adoption of EHRs and increased government funding to build cancer registries—key drivers for market growth
11.2.2 CANADA
11.2.2.1 Government initiatives to encourage cancer research and support data collection for cancer registries to contribute to market growth
11.3 EUROPE
11.3.1 UK
11.3.1.1 Initiatives to promote and develop cancer registration in the UK to drive the growth of this market
11.3.2 GERMANY
11.3.2.1 Growing incidence of cancer and ongoing research activities to drive demand for registry software
11.3.3 FRANCE
11.3.3.1 Growing emphasis on healthcare interoperability to drive the market for integrated cancer patient registry software in France
11.3.4 REST OF EUROPE (ROE)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 MARKET PLAYER RANKING
12.3 COMPETITIVE SITUATION AND TRENDS
12.3.1 PRODUCT ENHANCEMENTS
12.3.2 ACQUISITIONS
12.3.3 COLLABORATIONS
13 COMPANY PROFILES
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 ONCO, INC.
13.2 C/NET SOLUTIONS
13.3 ELEKTA AB (PUB)
13.4 ROCKY MOUNTAIN CANCER DATA SYSTEMS
13.5 ELECTRONIC REGISTRY SYSTEMS, INC.
13.6 MCKESSON CORPORATION
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 RELATED REPORTS
14.4 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 2 STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 3 NORTH AMERICA: STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 4 EUROPE: STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 6 NORTH AMERICA: INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 EUROPE: INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 9 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY COUNTRY/REGION, 2017–2024 (USD MILLION)
TABLE 12 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY REGION, 2017-2024 (USD MILLION)
TABLE 13 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2017-2024 (USD MILLION)
TABLE 14 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY COUNTRY/ REGION, 2017-2024 (USD MILLION)
TABLE 15 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 16 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 20 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2019–2024 (USD MILLION)
TABLE 21 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2019–2024 (USD MILLION)
TABLE 22 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 23 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 29 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 30 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 34 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 36 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 38 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 39 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY REGION, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 43 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 44 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 45 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 46 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 48 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 49 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 52 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 53 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 54 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 55 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 57 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 58 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 59 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 60 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 61 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 62 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 63 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 65 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 66 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 67 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 68 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 71 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 72 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 73 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 74 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 76 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 77 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 78 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 79 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 81 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 82 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 83 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 84 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 86 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 87 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 88 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 89 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 91 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 92 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 93 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 94 PRODUCT ENHANCEMENTS, 2016–2018
TABLE 95 ACQUISITIONS, 2016–2018
TABLE 96 COLLABORATIONS, 2016–2018
TABLE 1 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 2 STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 3 NORTH AMERICA: STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 4 EUROPE: STANDALONE CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 6 NORTH AMERICA: INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 EUROPE: INTEGRATED CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 9 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR ON-PREMISE MODELS, BY COUNTRY/REGION, 2017–2024 (USD MILLION)
TABLE 12 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY REGION, 2017-2024 (USD MILLION)
TABLE 13 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2017-2024 (USD MILLION)
TABLE 14 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CLOUD-BASED MODELS, BY COUNTRY/ REGION, 2017-2024 (USD MILLION)
TABLE 15 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 16 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR COMMERCIAL DATABASES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 19 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 20 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2019–2024 (USD MILLION)
TABLE 21 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PUBLIC DATABASES, BY COUNTRY, 2019–2024 (USD MILLION)
TABLE 22 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 23 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR CANCER REPORTING TO MEET STATE AND FEDERAL REGULATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PATIENT CARE MANAGEMENT, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 29 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 30 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR MEDICAL RESEARCH & CLINICAL STUDIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY REGION, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 34 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRODUCT OUTCOME EVALUATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 36 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 37 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 38 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR GOVERNMENT ORGANIZATIONS & THIRD-PARTY ADMINISTRATORS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 39 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY REGION, 2017–2024 (USD MILLION)
TABLE 40 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR HOSPITALS & MEDICAL PRACTICES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 43 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 44 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PRIVATE PAYERS, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 45 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY REGION, 2017–2024 (USD MILLION)
TABLE 46 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND MEDICAL DEVICE COMPANIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 48 CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY REGION, 2017–2024 (USD MILLION)
TABLE 49 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 52 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 53 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 54 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 55 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 57 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 58 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 59 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 60 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 61 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 62 US: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 63 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 64 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 65 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 66 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 67 CANADA: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 68 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 70 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 71 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 72 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 73 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 74 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 76 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 77 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 78 UK: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 79 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 GERMANY: PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 81 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 82 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 83 GERMANY: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 84 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 86 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 87 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 88 FRANCE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 89 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION)
TABLE 91 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2017–2024 (USD MILLION)
TABLE 92 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2017–2024 (USD MILLION)
TABLE 93 ROE: CANCER PATIENT REGISTRY SOFTWARE MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 94 PRODUCT ENHANCEMENTS, 2016–2018
TABLE 95 ACQUISITIONS, 2016–2018
TABLE 96 COLLABORATIONS, 2016–2018
LIST OF FIGURES
FIGURE 1 CANCER PATIENT REGISTRY SOFTWARE: MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2019 VS. 2024 (USD MILLION)
FIGURE 9 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 10 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2019 VS. 2024 (USD MILLION)
FIGURE 11 RESEARCH CENTERS SEGMENT IS EXPECTED TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 RISING PRESSURE TO IMPROVE THE QUALITY OF CARE AND REDUCE HEALTHCARE COSTS TO DRIVE MARKET GROWTH
FIGURE 13 INTEGRATED SOFTWARE SEGMENT TO GROW AT THE FASTEST RATE DURING THE FORECAST PERIOD
FIGURE 14 ON-PREMISE MODELS TO HOLD THE LARGEST SHARE OF THE MARKET IN 2019
FIGURE 15 COMMERCIAL DATABASE SEGMENT TO DOMINATE THE MARKET IN 2019
FIGURE 16 CANCER REPORTING TO MEET STATE & FEDERAL REGULATIONS SEGMENT TO DOMINATE THE MARKET IN 2019
FIGURE 17 HOSPITALS AND MEDICAL PRACTICES SEGMENT TO DOMINATE THE MARKET IN 2019
FIGURE 18 CANCER PATIENT REGISTRY SOFTWARE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 19 INTEGRATED SOFTWARE SEGMENT IS EXPECTED TO REGISTER HIGH GROWTH DURING THE FORECAST PERIOD
FIGURE 20 CLOUD-BASED MODELS SEGMENT IS EXPECTED TO WITNESS THE HIGHER CAGR DURING THE FORECAST PERIOD
FIGURE 21 COMMERCIAL DATABASES SEGMENT TO DOMINATE THE CANCER PATIENT REGISTRY SOFTWARE MARKET DURING THE FORECAST PERIOD
FIGURE 22 MEDICAL RESEARCH & CLINICAL STUDIES SEGMENT IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 23 RESEARCH CENTERS - THE FASTEST-GROWING END-USER SEGMENT IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET
FIGURE 24 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
FIGURE 25 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET FROM 2016 TO NOVEMBER 2018
FIGURE 27 CANCER PATIENT REGISTRY SOFTWARE MARKET PLAYER RANKING, 2018
FIGURE 28 ELEKTA AB (PUB): COMPANY SNAPSHOT
FIGURE 29 MCKESSON CORPORATION: COMPANY SNAPSHOT
FIGURE 1 CANCER PATIENT REGISTRY SOFTWARE: MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 8 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT MODEL, 2019 VS. 2024 (USD MILLION)
FIGURE 9 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY DATABASE TYPE, 2019 VS. 2024 (USD MILLION)
FIGURE 10 CANCER PATIENT REGISTRY SOFTWARE MARKET, BY FUNCTIONALITY, 2019 VS. 2024 (USD MILLION)
FIGURE 11 RESEARCH CENTERS SEGMENT IS EXPECTED TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 RISING PRESSURE TO IMPROVE THE QUALITY OF CARE AND REDUCE HEALTHCARE COSTS TO DRIVE MARKET GROWTH
FIGURE 13 INTEGRATED SOFTWARE SEGMENT TO GROW AT THE FASTEST RATE DURING THE FORECAST PERIOD
FIGURE 14 ON-PREMISE MODELS TO HOLD THE LARGEST SHARE OF THE MARKET IN 2019
FIGURE 15 COMMERCIAL DATABASE SEGMENT TO DOMINATE THE MARKET IN 2019
FIGURE 16 CANCER REPORTING TO MEET STATE & FEDERAL REGULATIONS SEGMENT TO DOMINATE THE MARKET IN 2019
FIGURE 17 HOSPITALS AND MEDICAL PRACTICES SEGMENT TO DOMINATE THE MARKET IN 2019
FIGURE 18 CANCER PATIENT REGISTRY SOFTWARE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 19 INTEGRATED SOFTWARE SEGMENT IS EXPECTED TO REGISTER HIGH GROWTH DURING THE FORECAST PERIOD
FIGURE 20 CLOUD-BASED MODELS SEGMENT IS EXPECTED TO WITNESS THE HIGHER CAGR DURING THE FORECAST PERIOD
FIGURE 21 COMMERCIAL DATABASES SEGMENT TO DOMINATE THE CANCER PATIENT REGISTRY SOFTWARE MARKET DURING THE FORECAST PERIOD
FIGURE 22 MEDICAL RESEARCH & CLINICAL STUDIES SEGMENT IS EXPECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 23 RESEARCH CENTERS - THE FASTEST-GROWING END-USER SEGMENT IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET
FIGURE 24 NORTH AMERICA: CANCER PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
FIGURE 25 EUROPE: CANCER PATIENT REGISTRY SOFTWARE MARKET SNAPSHOT
FIGURE 26 KEY DEVELOPMENTS IN THE CANCER PATIENT REGISTRY SOFTWARE MARKET FROM 2016 TO NOVEMBER 2018
FIGURE 27 CANCER PATIENT REGISTRY SOFTWARE MARKET PLAYER RANKING, 2018
FIGURE 28 ELEKTA AB (PUB): COMPANY SNAPSHOT
FIGURE 29 MCKESSON CORPORATION: COMPANY SNAPSHOT
